India's oxytocin ban delayed by a month as Delhi HC hears cases against it

Oxytocin is a hormone drug used to induce labour in pregnant women and stall post-partum bleeding.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2oqbm2U
via IFTTT

Read More

Gland Pharma seeks pitches from investment bankers to go public

Gland Pharma, which is owned 74% by the Chinese major, is seeking a valuation of $3 billion, which is more than twice that of the valuation it was bought in September 2017.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2NyGrwn
via IFTTT

Read More

Fortis CFO Gagandeep Singh Bedi quits

The Board of Directors of the company at its meeting held today have considered Bedi's resignation from the services of the company, and accepted the same.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2wtY5uD
via IFTTT

Read More

Domestic pharma players eye Bharat Serums acquisition

The two funds together hold a 23% stake and the remainder is with the Daftary family.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2wmFjoY
via IFTTT

Read More

Glenmark inks licensing pact for generic Tiotropium Bromide dry powder inhaler in Western Europe

This is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/Salmeterol dry powder inhaler, the company said.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2PHiuEF
via IFTTT

Read More

Your habit of throwing medicines is breeding superbugs that are hard to cure

"Superbugs" are strains of bacteria that are resistant to the majority of antibiotics commonly used today to treat infections.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2NvXGOH
via IFTTT

Read More

Govt asks districts to weed out names that should not be in list of Ayushman Bharat beneficiaries

The National Health Agency sent a circular to districts asking them to weed out any families identified as eligible for the Ayushman Bharat-National Health Protection Mission, but who in reality are financially well off.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2PR1WKu
via IFTTT

Read More

Maharashtra FDA ex-chief accuses DCGI of delaying action against J&J

In a telephonic interview to ET, Zagade also questioned the basis on which the drug controller’s office re-issued the import licence for the articular surface replacement (ASR) hip implants even though the company had voluntarily recalled the product in 2010.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2PeOD5h
via IFTTT

Read More

Lupin gets USFDA nod to market its postherpetic neuralgia drug

The company's tablets are generic version of Pfizer Inc's Neurontin tablets in the same strengths, Lupin said.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2BTUbAp
via IFTTT

Read More

Modicare: Rule of hospital stay eased for cancer fighters

Guidelines of the tumour board have been adopted to ensure patients do not have to pay out of their pocket.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2PKN8x0
via IFTTT

Read More

India's health ministry still 'deliberating' on findings on J&J's faulty hip implants, says JP Nadda

J&J, through subsidiary DePuy Orthopaedics, had issued a global recall of the implant system, called ASR Hip System, in 2010 after it received "new information" from the UK National Joint Registry, a J&J spokesperson earlier said.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2wrsjxK
via IFTTT

Read More

Lupin launches contraceptive drug in the US market

The company has launched the product in the US after having received approval from the USFDA earlier, Lupin said in a BSE filing.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2wq8yq8
via IFTTT

Read More

USFDA conducts inspection of Sun Pharma’s Halol site: Sources

The USFDA inspection at Halol in 2015 had resulted in 23 observations – a set of deficiencies in the manufacturing processes.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2PaCQVQ
via IFTTT

Read More

Not all is well with India's corporate hospital chains

India’s corporate hospital chains are faced with heavy strain on their financial health, thanks to spiraling costs and regulatory controls on pricing.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2P23OPg
via IFTTT

Read More

22 new AIIMS coming up across the country: J P Nadda

He also said ensuring the highest standards of medical education was a top priority for the government.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2MQs616
via IFTTT

Read More

J&J may have to compensate for faulty hip implants

The reason it has taken so long to arrive at this decision is because there is currently no provision to compensate patients for drugs and devices that are already approved in the market, said officials.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2BRzYLo
via IFTTT

Read More

BRS Group highest bidder for SevenHills hospital

Despite being endorsed by a Bollywood superstar, SevenHills failed to take off in Mumbai on the back of poor location and mismanagement.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2wd4ESb
via IFTTT

Read More

Lupin gets EIR from USFDA for Nagpur facility

Commenting on the development, Lupin MD Nilesh Gupta said, "The successful completion of the Nagpur facility inspection is a positive development as we continue our journey to meet and exceed international regulatory standards."

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2P3NptI
via IFTTT

Read More

US Medicare could have saved $1 billion by substituting branded drugs, says study

The revelation is significant for India since Indian pharma companies supply 40 per cent of generic drugs consumed in the US.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2wrhRGy
via IFTTT

Read More

Sunil Godhwani responsible for Group's woes: Singh Brothers

Godhwani had stepped down as the chairman and MD in July 29, 2016. Subsequently, he assumed charge of the CEO in Religare Enterprises.

from Healthcare/Biotech-Industry-The Economic Times https://ift.tt/2w8M9OW
via IFTTT

Read More